Long intergenic noncoding RNAs (lincRNAs) have critical regulatory roles in cancer biology; however, the contributions of lincRNAs to esophageal squamous cell carcinoma (ESCC) have been infrequently explored. The aim of this study was to explore the contribution of lincRNAs, located at ESCC susceptibility loci identified by genome-wide association studies, to the risk and prognosis of ESCC. The associations between lincRNAs and the risk and prognosis of ESCC were analyzed in 358 diagnosed patients from eastern China, and the findings were validated in 326 additional patients from southern China. Functional relevance of lincRNAs was further examined by biochemical assays. We found that lincRNA-uc002yug.2 was commonly overexpressed in ESCC compared with paired peritumoral tissue in eastern and southern Chinese populations. The expression levels of lincRNA-uc002yug.2 in ESCC might be a prognostic factor for survival. Moreover, lincRNA-uc002yug.2 promoted a combination of RUNX1 and alternative splicing (AS) factors in the nucleus to produce more RUNX1a, the short isoform and inhibitor of RUNX1, and reduce CEBPα (CCAAT/enhancerbinding protein-α) gene expression, thereby promoting ESCC progression. These results indicated that lincRNA-uc002yug.2 might involve in AS of RUNX1/AML1 and serve as a predictor for esophageal cancer and prognosis.
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is the eighth most common malignancy worldwide. 1 Therapies such as esophagectomy, chemotherapy and radiotherapy are frequently used to treat ESCC; however, the long-term outcome of this cancer is still dismal, with 5-year survival rates around 30%. 2 The occurrence and development of human neoplasms, including ESCC, 3 involve a multistep process of genetic alterations. Genetic susceptibility, environmental factors and gene-environment interactions are thought to contribute to the development of ESCC. 4 Recently, genetic variants in ESCC have been explored and susceptibility loci have been identified by several genome-wide association studies (GWAS). 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] GWAS is a powerful strategy that identifies the presence of sequence variation, which covers the entire genome, to select disease-related loci. GWAS of cancer susceptibility loci have been mainly identified in the noncoding portions of the genome, some of which may be transcribed. 13 It has been revealed that most of the human genome is transcribed, generating a sizable repertoire of long noncoding RNAs (lncRNAs) that map to intronic and intergenic regions, and o 1% of these have been characterized. [14] [15] [16] [17] Recently, a few noncoding transcripts, which have an active role in RNA processing, gene regulation and particularly in carcinogenesis, have been characterized in mammalian species. [18] [19] [20] [21] Although lncRNAs might involve in various human diseases, the underlying molecular mechanisms are still largely unknown.
The altered expression of several lncRNAs has been reported in various human tumors. [22] [23] [24] [25] LncRNAs might act as modular scaffolds for protein-chromatin interactions. 26 In addition, some antisense long intergenic noncoding RNAs (lincRNAs) silence genes in cis. 27 Here we identified 19 lincRNAs by using bioinformatic analysis on the basis of GWAS-based ESCC reports and human lncRNAs database, 28 and UCSC, Ensembl and Refseq databases. We further explored whether these lincRNAs contributed to the risk and prognosis of ESCC in eastern and southern Chinese populations.
RESULTS
LincRNA-uc002yug.2 was highly expressed in ESCC tissue and indicated a poor prognosis The clinical information and demographic characteristics of the 684 ESCC patients included in this study were shown in Table 1 . We identified the expression of 19 candidate lincRNAs in 358 pairs of ESCC and non-tumor samples in eastern China (Suzhou), and noted that only lincRNA-uc002yug.2 was remarkably upregulated (3.25-fold, P o0.001) in ESCC. Then, in 326 pairs of ESCC and adjacent tissues in southern China (Guangzhou), we found that lincRNA-uc002yug.2 was significantly upregulated (4.28-fold, P = 0.023) in ESCC. Pooled analysis also demonstrated that lincRNA-uc002yug.2 levels were significantly higher (3.63-fold, P = 0.006) in tumor tissues than in adjacent tissues (Figure 1a ).
ESCC patients were classified into high (41.20-fold increase), medium (0.80-1.20-fold increase) and low (o 0.80-fold decrease) lincRNA-uc002yug.2 groups based on the expression levels in cancerous tissues at/above or below the levels in corresponding peritumoral tissues. 29 We further examined the correlation between lincRNA-uc002yug.2 expression levels and the overall survival (OS) of ESCC patients. The subgroups were compared using the log-rank test and Kaplan-Meier survival curves in the discovery set, the validation set and the pooled set ( Figure 1b and Table 2 ). In the univariate analysis, patients in the discovery set (Suzhou) with high levels of lincRNA-uc002yug.2 had poorer OS than those in the low lincRNA-uc002yug.2 group (hazard ratio (HR) = 2.39; 95% confidence interval (CI) = 1.25-4.60; P = 0.0062). In the multivariate analysis, a Cox proportional hazard model was adjusted for sex, age, body mass index (BMI), family history, smoking status, drinking status, pathological type and tumor stage, and high lincRNA-uc002yug.2 subgroup had poorer OS than the low lincRNA-uc002yug.2 subgroup (HR = 2.57; 95% CI = 1.31-5.03; P = 0.0021). These results were confirmed in the validation set (Guangzhou) with high lincRNA-uc002yug.2 displaying a consistent association with OS in the validation (HR = 2.67; 95% CI = 1. 38-5.19 ; P = 0.0007) and pooled data sets (HR = 2.61; 95% CI = 1.50-3.78; P o 0.0001).
LincRNA-uc002yug.2 was associated with alternative splicing of RUNX1
To determine the cellular characterization of lincRNA-uc002yug.2, we separated the nucleus from the cytoplasm, as indicated by the detection of GAPDH mRNA exclusively in the cytoplasmic fraction, and the detection of nucleus-retained U6 predominantly in the nuclear fraction. It revealed that most of the lincRNA-uc002yug.2 was detected in the nuclear fraction ( Figure 2a ).
We noted that the RUNX1/AML1 gene was located in the downstream of lincRNA-uc002yug.2 transcript. Three isoforms of RUNX1 (RUNX1a, RUNX1b and RUNX1c) were produced through alternative splicing (AS), and the short RUNX1 isoform (RUNX1a) was an important contributing factor for carcinogenesis. 30 It is interesting to note that a 277 -nucleotide intron region in RUNX1 pre-mRNA was adversely base complemented with lincRNA-uc002yug.2 transcript. Moreover, based on the online bioinformatics analysis: http://rbpdb.ccbr.utoronto.ca/, some protein factor binding sites (sap-49, FUS, Pum2, MBNL1, RBMX, RBM4, SFRS1 and ELAVL1, with 100% relative score) were detected on RUNX1 at this complemented region ( Supplementary Figure 1) . Thus, we hypothesized that lincRNA-uc002yug.2 might have a role in the AS of RUNX1 by affecting the binding affinity of these protein factors to produce more RUNX1a (Figure 2b ).
RNA fluorescence in situ hybridization (RNA FISH) using specific probes for lincRNA-uc002yug.2 transcript (red) and RUNX1 pre-mRNA (green) in Eca-109 ( Supplementary Figure 2A ) and TE-1 ( Figure 2c ) cells showed the localization of lincRNA-uc002yug.2 transcript and RUNX1 pre-mRNA, and lincRNA-uc002yug.2 was predominantly present in the nucleus. To further detect the lincRNA-uc002yug.2 expression pattern in esophageal cancer and adjacent tissues, we performed in situ RNA hybridization in the tissue chip using the QuantiGene ViewRNA ISH Tissue Assay (Affymetrix, Santa Clara, CA, USA), and also found that lincRNA-uc002yug.2 was predominantly present in the nucleus, and its expression was significantly higher in cancer tissues than in adjacent tissues ( Figure 2d ). We next performed RNA electrophoretic mobility shift assays (EMSAs) using biotin-labeled probes for the complemented region of RUNX1 including sap-49, FUS, Pum2, MBNL1, RBMX, RBM4, SFRS1 or ELAVL1 binding sites and unlabeled probes for the corresponding lincRNA-uc002yug.2 sequences. When using labeled probes only or with nuclear protein from Eca-109 cells (Figure 2e , lanes 1 and 2), no RNAprotein complex was detected. After adding the RNA duplex formed by unlabeled probes and labeled probes including MBNL1 or SFRS1 binding sites, as well as the use of nuclear protein from Eca-109 cells, significant levels of RNA-protein complexes were observed (Figure 2e , lane 4). Similar results were also obtained with nuclear extracts from TE-1 cells (Supplementary Figure 2B ). Supershift assays were then performed using antibodies against MBNL or SFRS1 with nuclear protein from Eca-109 cells ( Figure 2f ). We found that the RNA-protein complex was successfully supershifted with the anti-MBNL1 or anti-SFRS1 antibodies, and the RNA-protein complexes disappeared when the labeled probes were mutated. To validate the association between lincRNA-uc002yug.2 and the two splicing factors, we used anti-MBNL and anti-SFRS1 to perform RNA immunoprecipitation (RIP) assays using Eca-109 and TE-1 nuclear extracts, and confirmed the efficiency of immunoprecipitation by western blotting. Significant enrichment of the lincRNA-uc002yug.2 was consistently detected compared with the immunoglobulin G (IgG) control (Figure 2g and Supplementary Figure 2C ). When cells were treated with small interfering RNAs (siRNAs) against MBNL1 or SFRS1 (Supplementary Figure 2D and E), the enrichment of lincRNA-uc002yug.2 with MBNL1 and SFRS1 antibodies was significantly downregulated (Figure 2h ).
We also found a significant positive correlation (R 2 = 0.320, P = 0.003) between the transcriptional levels of lincRNA-uc002yug.2 and RUNX1a, and a negative correlation (R 2 = 0.174, P = 0.038) between lincRNA-uc002yug.2 and the other isoforms (RUNX1b and RUNX1c) in 25 ESCC tissues ( Figure 2i ). In addition, we stably transfected cells with lentivirus encoding lincRNA-uc002yug.2 and/or four short hairpin RNAs (shRNAs) against lincRNA-uc002yug.2 (shRNA-1, shRNA-2, shRNA-3 and shRNA-4) to construct cell lines with stable lincRNA-uc002yug.2 overexpression and underexpression (Supplementary Figure 3A) , and used shRNA-1-uc002yug.2-transfected cells as lincRNA-uc002yug.2-low cell lines. Then, we found that significantly higher levels of RUNX1a were consistently detected; however, the levels of RUNX1b and RUNX1c were decreased in lincRNA-uc002yug.2-high cells than in lincRNA-uc002yug.2-low cells , and in the control cells (P o0.001 in Eca-109 and P o0.001 in TE-1) (Supplementary Figure 3B ). The splicing program of RUNX1 was consequently disrupted in ESCC cells after treating with siRNAs for SFRS1 or MBNL1, and thus ruined the previous expression pattern of RUNX1a/b/c (Supplementary Figure 3C ).
RUNX1 affects CEBPα gene expression via conserved promoter and distal enhancer sites
Guo et al. 31 had reported that the deletion of RUNX1, as well as transduction of the dominant-inhibitory RUNX1a isoform, greatly reduced CCAAT/enhancer-binding protein-α (CEBPα) mRNA. 31 Besides, the function of CEBPα in cell proliferation arrest and tumor suppression had been extensively studied. [32] [33] [34] Here we found that more CEBPα mRNAs (Supplementary Figure 3D ) and proteins ( Figure 3a) were found in lincRNA-uc002yug.2-low cells. And, a significant negative correlation (R 2 = 0.162, P = 0.046) between the transcriptional levels of RUNX1a and CEBPα was found, whereas a significant negative correlation (R 2 = 0.246, P = 0.013) existed between the transcriptional levels of lincRNA-uc002yug.2 and CEBPα (Figure 3b ). Thus, we further explored whether the different levels of RUNX1a, which might be caused by lincRNA-uc002yug.2, affected cell proliferation and tumor growth indirectly via CEBPα.
Guo et al. 31 also found that the human CEBPα promoter retained a conserved 5′-GACCACG-3′ at − 273 bp, which matched the consensus for RUNX1 binding, 5′-(Pu)ACCPuCA-3′. Here lincRNA-uc002yug.2-low cells were subjected to chromatin immunoprecipitation (ChIP) using anti-RUNX1 and antiserum or normal mouse IgG, followed by genomic DNA PCR using oligonucleotides centered at − 270 bp of the CEBPα gene promoter, and the interaction of RUNX1 with the cellular CEBPα promoter was detected ( Figure 3c ). Then, we cloned this promoter region to construct reporter plasmids ( Figure 3d ) and further performed luciferase assays ( Figure 3e ). The luciferase activities were increased by 1.8-3-fold in lincRNA-uc002yug.2-low cells than in control cells and in lincRNA-uc002yug.2-high cells. According to the work of Guo et al., 31 four RUNX1 binding sites were in a conserved 450 bp CEBPα+37 kb distal element. The interaction of RUNX1 with the cellular CEBPα enhancer was detected ( Figure 3f ). In addition, we cloned a 497-bp enhancer segment containing the four RUNX1 binding sites into the upstream of the CEBPα promoter and the luciferase cDNA ( Figure 3g ). The luciferase activity was increased significantly (Figure 3h ) in lincRNA-uc002yug.2-low cells than in lincRNA-uc002yug.2-high cells.
Effects of lincRNA-uc002yug.2 on cellular proliferation, migration and invasion To evaluate the effects of lincRNA-uc002yug.2 on cell biological behaviors, biochemical assays were performed with lincRNA-uc002yug.2 stable over-and underexpressing cell lines. Cell Counting Kit-8 assays indicated that the cell proliferation was consistently promoted in Eca-109 (P o0.001) and TE-1 cells (P = 0.012) with high lincRNA-uc002yug.2, and the cell proliferation was reduced consistently in lincRNA-uc002yug.2-low-Eca-109 cells (P o 0.001) and in lincRNA-uc002yug.2-low-TE-1 cells (P = 0.001), compared with the control cells on the fourth day ( Figure 4a ). The colony formation abilities of cells with higher expression of lincRNA-uc002yug.2 markedly increased, and it was notably suppressed in lincRNA-uc002yug.2-low cells compared with the control cells ( Figure 4b ). Cells with high lincRNA-uc002yug.2 showed significantly increased migration and invasion when compared with negative controls, and cells with lower expression of lincRNA-uc002yug.2 decreased migration and invasion ( Figure 4c ). In Figure 4d , we found that the percentage of cells in the G2/M phase was significantly increased (P = 0.013 in Eca-109 and P = 0.040 in TE-1 cells), whereas the percentage of cells in the G1/S phase was decreased (P = 0.006 in Eca-109 and P = 0.004 in or Eca-109-shRNA1-uc002yug.2 cells) or TE-1 cells (TE-1-empty vector, TE-1-lincRNA-uc002yug.2 or TE-1-shRNA1-uc002yug.2 cells) at the same time (five mice per group). As shown in Figure 4e , tumor growth from Eca-109-lincRNA-uc002yug.2 cell xenografts began 3 days earlier than that from Eca-109-empty vector cell xenografts, and the tumor volume after 4 weeks in the former group was 991.43 ± 48.18 mm 3 ,~380 mm 3 larger than the latter. In contrast, the growth of tumors from Eca-109-shRNA1-uc002yug.2 cell xenografts was inhibited when compared with that of tumors formed from Eca-109-empty vector cell xenografts. Moreover, we observed similar results with the transfected TE-1 cell lines. To investigate whether these findings have general validity, we injected Eca-109 and TE-1 wild-type cells into mice and found that the tumor growth was comparable to that caused by Eca-109-empty vector and TE-1-empty vector cell xenografts (data not shown).
DISCUSSION
In this study, we investigated the effects of 19lincRNA transcripts located at ESCC susceptibility loci identified by GWAS on the risk of developing ESCC, and found that ESCC patients with high lincRNA-uc002yug.2 expressions had an increased risk of ESCC and significantly reduced OS in Chinese populations, suggesting that it might be a valuable new biomarker for ESCC.
LincRNAs, which had conserved genomic locations, had crucial biological roles during embryonic development with conserved functionality, 28 and this suggested that the location of lincRNAs had a critical significance. In this study, we noted that the RUNX1 gene was located downstream of the lincRNA-uc002yug.2 transcript, and analyzed a 277-nucleotide adversely complemented region between the lincRNA-uc002yug.2 transcript and the RUNX1 pre-mRNA. RUNX1 is a transcription factor that has a crucial role in several tumors such as breast cancer 35 and epithelial cancer. 36 It was found that the deletion of RUNX1 existed in some of esophageal tumors, and this suggested that RUNX1 has a tumorsuppressing role in esophageal tumors. 37 The human RUNX1 gene generates three alternatively spliced variants: RUNX1a, RUNX1b and RUNX1c. Ito et al. 38 reported that the short isoform, RUNX1a, is thought to be a potential functional antagonist of RUNX1b and RUNX1c. It has been demonstrated that RUNX1a has a key role in stem/progenitor cells. 39 AS of mRNA precursors, which markedly affects human development, provides an important means of genetic control and is a crucial step in the expression of most genes, and its misregulation contributes to many human diseases. 40 With the extensive studies on the mechanisms of AS, we have begun to realize the diversity and complexity of AS regulation by an intricate protein-RNA network. In addition to a splicing code that integrates the role of RNA, the influence of chromatin and noncoding RNA in AS regulation was discovered. 41 In our study, we found that lincRNA-uc002yug.2 facilitated protein factors (SFRS1 and MBNL) onto RUNX1 pre-mRNA. SFRS1 is a prototypical SR protein that participates in both constitutive and AS. 42 MBNL1, a member of the muscleblind-like RNA-binding protein family, is involved in ES cell-specific AS. 43 Our results suggested that lincRNA-uc002yug.2 could recruit AS factors (SFRS1 and MBNL1) onto RUNX1 to promote its AS by the formation of regional RNA duplexes, to produce more RUNX1a, and then promote carcinogenesis. We found that RUNX1 affects CEBPα gene expression via conserved promoter and distal enhancer sites. Several studies indicate that CEBPα has a crucial role in cell proliferation arrest and tumor suppression via various ways. Kumar et al. 44 reported that CEBPα was involved in mammary carcinogenesis and regulated the human TERT (telomerase reverse transcriptase) gene. 44 It was found that CEBPα directly interacted with cyclindependent kinase 2/cyclin-dependent kinase 4 and arrested cell proliferation. 32 Muller et al. 45 found that the antiproliferation activity of CEBPα critically depended on the components of the SWI/SNF core complex. 45 Here we demonstrated that lincRNA-uc002yug.2 might facilitate AS of RUNX1 by affecting the affinity between AS factors and RUNX1 to decrease the expression of RUNX1 and increase the expression of RUNX1a, resulting in reduced CEBPα gene expression, and further promote cell proliferation and tumor growth ( Figure 5 ).
To the best of our knowledge, the involvement of lincRNAs in AS of RUNX1 has not been investigated, and its association with ESCC has not been adequately examined. Our study is the first to demonstrate a significant association between lincRNA-uc002yug.2 and ESCC risk and prognosis. Nevertheless, because ESCC is a complex disease, larger-scale mechanistic studies are warranted to confirm the real contribution of lincRNA-uc002yug.2 to ESCC in Chinese populations or to investigate the association between lincRNA-uc002yug.2 and different tumors in different ethnicities, limiting the confounding effect of population heterogeneity.
In conclusion, our study demonstrates that lincRNA-uc002yug.2 might increase the risk of ESCC in eastern and southern Chinese populations, and might serve as a predictor of poor ESCC prognosis and influence the AS of RUNX1.
MATERIALS AND METHODS

Patients and clinical samples
A total of 684 patients with histologically confirmed ESCC participating in this study were ethnically homogenous Han Chinese derived from eastern and southern China (Table 1 ). In eastern China, 358 pairs of fresh ESCC and adjacent non-cancerous tissue samples were randomly selected from patients undergoing esophagectomy in the Suzhou city. Another 326 pairs of fresh esophageal tissues were collected in southern China (Guangzhou) and used for validation. Coupled non-cancerous tissues were isolated from at least 5 cm away from the tumor border and were shown to lack tumor cells by microscopy. In this study, all patients were identified as ESCC by pathological examination and were not given any anticancer treatments, complete resection of all tumor nodules was verified by the cut surface being free of cancer by pathological examination, the complete clinicalpathologic and follow-up data were available and patients died of other diseases or accidents were excluded. Tumor staging and pathological type were evaluated according to the 2002 American Joint Committee on Cancer staging system. Informed consent was obtained from each participant, and this study was approved by the Medical Ethics Committee of Soochow University and the Institutional Review Boards of Guangzhou Medical University.
Follow-up
For the OS rate study, each patient saw his or her doctor during the followup period for assessment every 3 months in the first year, every 6 months in the second year and annually thereafter until 2013, and dates of death were obtained from in-patient and outpatient records or from the patients' families through telephone follow-up. A computed tomography scan of the chest and abdominal ultrasound were performed every assessment. The OS was defined as the length of time between diagnosis and death or the last follow-up examination.
LincRNAs selection
We searched for published literature regarding associations between variants identified in GWAS and risk of ESCC, and these relevant literatures were made available in the PubMed database up to 2013. We also manually searched the reference lists in selected articles and abstracts published at major international conferences. The major exclusion criteria were (1) reviews, tutorials, letters and editorials; (2) not using chip technology; (3) not a case-control design; and (4) overlapping data or data dumped by the latest reports. We scoured the reported susceptibility loci (10q23, 20p13, 5q11, 6p21, 12q24, 21q22, 7p15.3, 4q23, 16q12.1, 17q21, 22q12, 3q27, 17p13, 18p11, 2q22, 13q33 and 18q12) to find lncRNAs within an 1-Mb range of these loci, in either direction (a total span of 2 Mb), according to human lncRNA database. 31 LncRNAs overlapped with proteincoding human genes were excluded on the basis of the information at UCSC, Ensembl and Refseq databases. Finally, 19 lincRNAs were selected and further identified in the cohort of our ESCC samples and paired adjacent tissues in quantitative real-time PCR (qRT-PCR) analysis. UCSC, Ensembl and Refseq databases. Finally, 19 lincRNAs were selected and 
Subcellular fractionation
The human ESCC cell lines (TE-1 and Eca-109) were purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Shanghai Institute of Cell Biology (Shanghai, China). Cytoplasmic and nuclear fractions were collected from cells as the Nuclear/Cytoplasmic Isolation Protocol (Biovision, Milpitas, CA, USA).
Lentiviral production and transduction
The full length of human lincRNA-uc002yug.2 was cloned into the lentiviral expression vector pLVX-IRES-neo (Clontech Laboratories Inc., San Francisco, CA, USA). The shRNAs of human lincRNA-uc002yug.2 lentivirus vector were obtained from GenePharma (Shanghai, China). Using a three-plasmid transient co-transfection method (Lenti-T HT packaging mix; Clontech Laboratories Inc.), replication-defective vesicular stomatitis virus-Gpseudotyped viral particles were packaged in human embryonic kidney cells LentiX 293T (Clontech Laboratories Inc.). Lentivirus were harvested and concentrated. For transduction, TE-1 and Eca-109 cells were infected with the control lentivirus (empty vector containing only, without lincRNA-uc002yug.2 fragment), lincRNA-uc002yug.2 lentivirus and shRNA-uc002yug.2 lentivirus. After 48 h of transduction, the cells were stably selected with G418 at 500 μg/ml (Gibco, Lyon, France), and the drug-resistant cell populations were used for subsequent studies.
QRT-PCR analysis
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from tissues and cell lines. An aliquot of total RNA (1 μg) was reversetranscribed into single-strand complementary DNA using the M-MLV First Strand Kit (Invitrogen). The relative levels of RNA were detected using the ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA) with SYBR-Green Mix (Takara Bio, Otsu, Japan) and GAPDH as the internal control.
RNA FISH assay
RNA FISH experiments were performed with FISH Detection Kit (Biolink, Guangzhou, China) in ESCC cell lines. Fluorescence-labeled probes specially for lincRNA-uc002yug.2 (red) and RUNX1 pre-mRNA (green) were used ( Supplementary Table 1 ). RNA in situ hybridization (RNA ISH) assays were performed in the tissue chip prepared from 30 pairs of esophageal cancer and adjacent tissues, using the QuantiGene ViewRNA ISH Tissue Assay (Affymetrix) protocol. Oligonucleotide probe specially for lincRNA-uc002yug.2 was designed commercially by Affymetrix. Hybridization signal was detected with a confocal laser scanning microscope (Leica, Solms, Germany).
Electrophoretic mobility shift assay
RNA EMSA was performed using LightShift Chemiluminescent RNA EMSA Kit (Pierce, Rockford, IL, USA) with nuclear extracts of TE-1 and Eca-109 cells. Single-stranded RNA probes were synthesized corresponding to the protein factors consensus binding sites from the paired region between lincRNA-uc002yug.2 and RUNX1 pre-mRNA, and oligonucleotides from RUNX1 pre-mRNA were biotin labeled at 5′ end (Invitrogen). For supershift assays, antibodies for MBNL and SFRS1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.
RNA immunoprecipitation
We performed RIP experiments using Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Antibodies for MBNL and SFRS1 (Santa Cruz Biotechnology) were diluted at 1:200. Total RNAs (input controls) and isotype controls (IgG) were assayed simultaneously.
Chromatin immunoprecipitation
We performed ChIP assay using the EZ ChIPTM Chromatin Immunoprecipitation Kit (Millipore) according to its manual. Chromatin was sonicated into 200-to 1000-bp fragments to crosslink. Then, the chromatin was immunoprecipitated using anti-RUNX1 (Santa Cruz Biotechnology) antibodies and normal mouse IgG was used as a negative control.
Western blotting assay
Extracts corresponding to cells, tissues or immunoprecipitation samples were prepared by detergent lysis buffer. Sixty micrograms of total proteins was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to PVDF membrane (Millipore). Antibodies for SFRS1, MBNL1, RUNX1, CEBPα or β-actin (Santa Cruz Biotechnology) were used. The proteins were detected with a Phototope-Horseradish Peroxidase Western Blot Detection Kit (Cell Sigaling Technology, Danvers, MA, USA).
Reporter assay
A 500-bp DNA fragment centered at − 270 bp of CEBPα promoter was cloned into the pGL3-basic vector (Promega, Madison, WI, USA). We named this plasmid as pGL3-CEBPα promoter. A 497-bp DNA segment containing the putative +37-kb enhancer was positioned upstream of the CEBPα promoter in pGL3-CEBPα promoter. We named this plasmid as pGL3-CEBPα-c promoter. Cells were seeded at 1 × 10 5 cells per well in 24-multiwell plates (Becton Dickinson Biosciences, Bedford, MA, USA). Sixteen hours later, cells were transfected using Lipofectamine 2000 (Life Technologies, Rockville, MD, USA), co-transfected with 800 ng reporter plasmid and 160 ng pRL-SV40 (Luciferase Assay System; Promega). Twentyfour hours later, cells were collected to detect Renilla luciferase activity with the Dual-Luciferase Reporter Assay System (Promega) in TD-20/20 luminometer (Turner Biosystems, Sunnyvale, CA, USA). Results were expressed as a ratio of luciferase activity to pRL-SV40.
Cell cycle analysis
Cells were collected and fixed in 70% ethanol overnight at 4°C. Subsequently, we labeled single-cell suspensions with 50 μg/ml propidium iodide (Sigma, St Louis, MO, USA) and analyzed using flow cytometry. Using the FlowJo software (Treestar Inc., Ashland, OR, USA), 10 000 cells were evaluated and the percentage of cells in the G2 phase was denoted by the 2N population phase.
Cell viability assay
Cells were seeded in 96-well flat-bottomed plates, and 2000 cells per 100 μl of cell suspension were seeded in each well. Cell viability was measured by Cell Counting Kit-8 (Dojindo Laboratory, Kumamoto, Japan), and the absorbance of each well was read at 450 nm using a microplate reader (MRX; Dynex Technologies, West Sussex, UK).
Colony formation assay
Four hundred cells were seeded in 65 mm culture dishes and allowed to grow until visible colonies formed in complete growth media (4 weeks). Cell colonies were fixed with cold methanol and stained with crystal violet (Invitrogen) for 30 min, washed, air dried, photographed and counted.
Transwell migration assay and Matrigel invasion assay
Cell migration and invasion ability were determined by Corning transwell insert chambers with 8 mm pores (Corning, Corning, NY, USA) and BD BioCoat Matrigel Invasion Chamber (Becton Dickinson Biosciences), respectively. About 2 × 10 4 (migration assay) or 2 × 10 5 (invasion assay) transfected cells in 200 μl serum-free RPMI-1640 medium were seeded in the upper well and the chambers were incubated for 48 h at 37°C to allow the cells to migrate to the lower well with RPMI-1640 medium plus 20% fetal bovine serum. Cells that had migrated or invaded through the membrane were fixed with methanol and stained with crystal violet (Invitrogen), imaged and counted.
Xenografts in mice
Female BALB/c nude mice that were 4-5 weeks of age were purchased from Shanghai Laboratory Animal Center at the Chinese Academy of Sciences. All the experiments carried out were in accordance with the guidelines approved by the Laboratory Animal Center of Soochow University. Transfected cells were diluted to a concentration of 5 × 10 6 /ml in physiological saline, and 0.1 ml of the suspension was injected subcutaneously into the posterior back of mice to construct tumor growth model. Five nude mice were used for each group. When a tumor was palpable, tumor growth was measured every other day by measuring the two largest perpendicular diameters with a caliper.
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Statistical analysis
All analyses were performed in a two-sided manner using SAS (version 9.1; SAS Institute, Cary, NC, USA), and Po0.05 was defined as statistically significant. For comparisons, one-way analyses of variance, Fisher's exact tests, χ 2 tests and two-tailed Student's t-tests were performed, as appropriate. OS curves were plotted according to the Kaplan-Meier method, with the log-rank test applied for comparison. All data were presented as mean ± s.d. All experimental assays were performed in triplicate.
